Patents by Inventor Koji Sakanaka

Koji Sakanaka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200147222
    Abstract: The present invention addresses the problem of providing a novel application of meglumine or a salt thereof. The present invention is an antiseptic agent consisting of meglumine or a salt thereof, and a pharmaceutical composition comprising the antiseptic agent according to the present invention, and pertaining to: a pharmaceutical composition which does not comprise benzalkonium chloride and which is placed in a reusable container; a product that comprises the pharmaceutical composition comprising the antiseptic agent according to the present invention and a reusable container; and a method of improving the antiseptic effect of the pharmaceutical composition by comprising meglumine or a salt thereof in the pharmaceutical composition that has been placed in the reusable container.
    Type: Application
    Filed: March 13, 2017
    Publication date: May 14, 2020
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventors: Toyomi Fujisawa, Koji Sakanaka, Shinya Umezaki
  • Patent number: 8686006
    Abstract: An object of the present invention is to provide a pharmaceutical composition that improves intestinal absorption of a compound having a structure represented by the general formula [1]. The composition containing a compound represented by the general formula [1] or a salt thereof and (b) a lipophilic substance improves intestinal absorption of the compound. In the formula, A represents —(NR4)—, —(CR5R6)— or the like; B represents an alkylene group or an alkenylene group; R1 represents an alkyl group, an alkenyl group or the like; R2 represents an adamantylalkyl group or the like; R3 represents an unsaturated heterocyclic ring; R4, R5 and R6 each represent a hydrogen atom or the like; and X represents an oxygen atom or the like.
    Type: Grant
    Filed: October 22, 2009
    Date of Patent: April 1, 2014
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Masayuki Umeda, Akio Kimura, Kenji Ueda, Koji Sakanaka
  • Publication number: 20120316158
    Abstract: Instillation of a 1.5% (w/v) levofloxacin ophthalmic solution three times a day, which is the dosage or dose regimen of the present invention, has features to cure bacterial conjunctivitis in a shorter time than instillation of a 0.5% (w/v) ophthalmic solution three times a day, which is the conventional dosage or dose regimen, and not to increase the rate of occurrence of side effects. Curing the ocular infection in a short time leads to shortening of the duration of exposure of the ocular-infection-causing bacterium to levofloxacin. Therefore, the levofloxacin ophthalmic solution in the dosage or dose regimen of the present invention is eventually expected to suppress emergence of the resistant bacterium resulting from the long-term use of the levofloxacin ophthalmic solution in the conventional dosage or dose regimen.
    Type: Application
    Filed: December 16, 2010
    Publication date: December 13, 2012
    Applicants: DAIICHI SANKYO COMPANY, LIMITED, SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Takashi Nagano, Koji Sakanaka, Masatsugu Nakamura, Kouichi Kawazu, Hajime Ibuki, Kayoko Sakamoto
  • Publication number: 20110201655
    Abstract: An object of the present invention is to provide a pharmaceutical composition that improves intestinal absorption of a compound having a structure represented by the general formula [1]. The composition containing a compound represented by the general formula [1] or a salt thereof and (b) a lipophilic substance improves intestinal absorption of the compound. In the formula, A represents —(NR4)—, —(CR5R6)— or the like; B represents an alkylene group or an alkenylene group; R1 represents an alkyl group, an alkenyl group or the like; R2 represents an adamantylalkyl group or the like; R3 represents an unsaturated heterocyclic ring; R4, R5 and R6 each represent a hydrogen atom or the like; and X represents an oxygen atom or the like.
    Type: Application
    Filed: October 22, 2009
    Publication date: August 18, 2011
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Masayuki Umeda, Akio Kimura, Kenji Ueda, Koji Sakanaka